11betamethyl nortestosterone dodecylcarbonate
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02754687)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Androgen ReceptorINHIBITOR
AR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 11betamethyl nortestosterone dodecylcarbonate
- 11βmethyl nortestosterone dodecylcarbonate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03298373 | Phase 1 | Nov 9, 2017 | Health Decisions, Los Angeles Biomedical Research Institute, National Institutes of Health (NIH), University of Washington |
| NCT02754687 | Phase 1 | Apr 1, 2016 | Health Decisions, Los Angeles Biomedical Research Institute, National Institutes of Health (NIH), University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Health Decisions | For profit | 2 | 2 | 1 | 2016 |
| Los Angeles Biomedical Research Institute | Academic/Hospital | 2 | 0 | 1 | 2016 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2016 |
| University of Washington | Academic/Hospital | 2 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1